Sop Ipc Qa
Sop Ipc Qa
1. OBJECTIVE
The purpose of this procedure is to establish a procedure for in-process checks performed
during production in order to monitor the process and ensure that the product conforms to its
specifications.
2. SCOPE
This procedure covers the In-Process checks of the manufacturing and packaging of
pharmaceutical products at Aspin Pharma (Pvt.) Ltd.
3. RESPONSIBILITIES
S. No. Action Responsibility
Production
Officer/QA Officer/
3.1. To perform and verify the in-process checks
Technical officer/
Designee
Manager QA(C&E)
To ensure that in-process checks procedure is properly implemented /Sr. Manager
3.2.
and compliance with the SOP. Production /
Designee
4. GENERAL REQUIREMENTS
4.1. Production Officer and QA Officer will ensure that all in process documents must be part
of batch document.
4.2. All in process documents must be retained along with batch document for a period of
expiry plus one year.
4.3. First In process check by Production Officer and QA officer or designee will be part of Line
clearance.
4.4. Viasala devices are installed with the help of high quality magnet for online monitoring the
Temperature and Humidity in GMP areas.
4.5. At the time of line clearance and in-process, QA officer and production officer will be verified
the temperature and humidity by wall mounted Vaisala devices (Where applicable).
4.6. During in-process monitoring, any non-compliance observed will be dealt by the SOP for In-
process Monitoring Observation ref. # QA/SOP/IPMO/243.
4.7. Frequency:
Process By Operator By Production Supervisor By QA
Over Printing At least one time At least one time in 2 hours. At least one time in 2
in 1 hour. hours.
Filling At least one time At least one time in 2 hours. At least one time in 2
in 1 hour. hours.
Weight of 10 tablets / At least one time At least one time in 2 hours At least one time in 2
capsules in 15 minutes hours.
Standard Operating Procedure
Title: In-Process Control & Checks
Document No. Version No. Supersede Date
QA/SOP/IPC/068 04 30.11.2021 Aspin Pharma (Pvt.) Ltd.
Preparation Date Review Date Page No. Plot No. 10 & 25, Sector
20, K.I.A, Karachi-
28.02.2023 27.02.2026 Page 2 of 8 Pakistan.
Weight Variation of At least one time At least one time in 2 hours. At least one time in 2
tablets / capsules in 1 hour. hours.
Hardness At least one time At least one time in 2 hours. At least one time in 2
in 1 hour. hours.
Thickness At least one time At least one time in 2 hours. At least one time in 2
in 1 hour. hours.
Disintegration time One time in a day One time in a day One time in a day
Friability One time in a day One time in a day One time in a day
Leak Test (Blistering) Start of batch / Start of batch / Start of batch /
Start of shift / start Start of shift / start of new Start of shift / start of new
of new roll, any roll, any breakdown and roll, any breakdown and
breakdown and once in every two hours. once in every two hours.
once in every two
hours.
Blistering At least one time At least one time in 2 hours. At least one time in 2
in 1 hour. hours.
Final Packaging N/A At least one time in 2 hours. At least one time in 2
hours.
4.8. Sampling
Steps No. of samples
(not readable)
Strip observed on line without product or short more
Empty strip/short product Major
than one tablet or capsule from blister packaging
4.8.6 Final Packaging
Wrong/mixed product Critical Mixed up or wrong product or packaging material
Standard Operating Procedure
Title: In-Process Control & Checks
Document No. Version No. Supersede Date
QA/SOP/IPC/068 04 30.11.2021 Aspin Pharma (Pvt.) Ltd.
Preparation Date Review Date Page No. Plot No. 10 & 25, Sector
20, K.I.A, Karachi-
28.02.2023 27.02.2026 Page 5 of 8 Pakistan.
6. DEFINITIONS
Standard Operating Procedure
Title: In-Process Control & Checks
Document No. Version No. Supersede Date
QA/SOP/IPC/068 04 30.11.2021 Aspin Pharma (Pvt.) Ltd.
Preparation Date Review Date Page No. Plot No. 10 & 25, Sector
20, K.I.A, Karachi-
28.02.2023 27.02.2026 Page 7 of 8 Pakistan.
7. REFERENCES USED:
S. No. Description
7.1. BS 6001 Part I 1991 Simple Normal Sampling Plan Level II
7.2. FDA 21cfr Part 211 - Current Good Manufacturing Practice For Finished Pharmaceuticals
Subpart F-Production and Process Controls sec.211.100 sampling & testing of in-process
and drug products.
7.3. WHO guidelines Annexure 3 point16.6,16.32,
8. REFERRED DOCUMENTS:
S. No. Document No. Description
8.1. QA/SOP/PLC/161 SOP for line clearance
8.2. QA/SOP/IPMO/243 SOP for In-process Monitoring Observation
10. HISTORY
Versio Effective
Issue Date Description of Change
n No. Date
01 N/A 17.05.2019 This is the 1st Version of SOP on new format as per
Management of documentation control (QA/SOP/MDC/001).
Standard Operating Procedure
Title: In-Process Control & Checks
Document No. Version No. Supersede Date
QA/SOP/IPC/068 04 30.11.2021 Aspin Pharma (Pvt.) Ltd.
Preparation Date Review Date Page No. Plot No. 10 & 25, Sector
20, K.I.A, Karachi-
28.02.2023 27.02.2026 Page 8 of 8 Pakistan.